Walker was the first to clearly demonstrate that strength temporarily improved in patients with myasthenia gravis when they were given physostigmine or Prostigmin (neostigmine). In a June 2, 1934 Lancet article, she noted: "The abnormal fatiguability in myasthenia gravis has been thought to be due to curare-like poisoning of the motor nerve-endings or of the 'myoneural junctions' in the affected muscles. It occurred to me recently that it would be worth while to try the effect of physostigmine, a partial antagonist to curare, on a case of myasthenia gravis at present in St. Alfege's Hospital, in the hope that it would counteract the effect of the unknown substance which might be exerting a curare-like effect on the myoneural junctions. I found that hypodermic injections of physostigmine salicylate did have a striking though temporary effect." Photographs showed the improvement in ptosis after treatment with physostigmine in "Mrs. M." No improvement occurred with control injections of water, pilocarpine, strychnine, adrenaline, ephedrine, or acetylcholine. Walker commented:
"I think that this effect of physostigmine on myasthenia gravis is important, though it is only temporary, for it improves swallowing and might tide a patient over a respiratory crisis. It supports the opinion that the fatiguability is due to a poisoning of the motor end-organs, or 'myoneural junctions,' rather than to an affection of the muscle itself. It may be significant that physostigmine inhibits the action of the esterase which destroys acetylcholine." Jolly (1895) suggested that physostigmine might be used in myasthenia gravis, and Murri (1896) tried physostigmine without success, as the patient did not tolerate the medicine. Remen (1932) observed temporary improvement with neostigmine (Prostigmin), but was mostly focused on the treatment of myasthenia with glycine.
In a 1979 letter, Derek Denny-Brown relayed how this treatment of Mrs. M with physostigmine came about. Denny-Brown visited St. Alfege's every two weeks. He diagnosed Walker's patient with myasthenia, and asserted that Walker had never heard of the disorder. Walker asked the cause, and Denny-Brown commented that it was unknown, but that it resembled curare poisoning. Denny-Brown stated that Walker did not know what that was. Denny-Brown recommended a strychnine-like medication and moved on to the next patient. Walker approached him while he was examining the next patient, and asked if she could try physostigmine. Denny-Brown stated that Walker had looked up the antidote to curare in a Burroughs Wellcome annual doctor's book. He agreed with the medication trial, even though he thought that it was unlikely to work. Denny-Brown noted:
"It was 2 weeks before I visited the hospital again, and this time she was waiting for me at the front entrance, in a great state of excitement. 'You must come and see my patient with myasthenia-she is cured.' Sure enough, there was no more weakness. . . . I am not very proud of my part in the discovery of the effect of prostigmine [sic] for if anything I attempted to discourage its trial!" The letter was written 45 years after the event, and was told from the point of view of only one of the two protagonists.
